Ironwood Pharmaceuticals (IRWD) Projected to Release Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $0.32 per share and revenue of $114.8430 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:30 PM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $106.51 million during the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. On average, analysts expect Ironwood Pharmaceuticals to post $1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $3.56 on Thursday. Ironwood Pharmaceuticals has a one year low of $0.71 and a one year high of $5.78. The company’s fifty day moving average price is $3.84 and its two-hundred day moving average price is $3.98. The company has a market capitalization of $580.49 million, a price-to-earnings ratio of 5.93 and a beta of 0.20.

Insider Buying and Selling at Ironwood Pharmaceuticals

In related news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider owned 313,680 shares in the company, valued at $1,417,833.60. This trade represents a 28.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Julie Mchugh sold 21,571 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the transaction, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in shares of Ironwood Pharmaceuticals by 248.3% in the third quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock worth $15,321,000 after purchasing an additional 8,337,672 shares during the period. Millennium Management LLC boosted its stake in Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after purchasing an additional 4,140,439 shares during the period. AQR Capital Management LLC grew its holdings in Ironwood Pharmaceuticals by 144.3% in the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after buying an additional 3,641,762 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Ironwood Pharmaceuticals by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,975,939 shares of the biotechnology company’s stock valued at $16,769,000 after buying an additional 58,603 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Ironwood Pharmaceuticals by 40.7% in the 4th quarter. Marshall Wace LLP now owns 4,424,002 shares of the biotechnology company’s stock worth $14,909,000 after buying an additional 1,279,863 shares during the period.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Zacks Research upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 1st. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.